Status:
UNKNOWN
Autologous Bone Marrow Mononuclear Cells Transplantation in Treating Diabetes Patients
Lead Sponsor:
Shandong University
Conditions:
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Eligibility:
All Genders
16-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The study evaluates the safety and efficiency of autologous bone marrow mononuclear cell transplantation in treating patients with type 1 or 2 Diabetes Mellitus. We hypothesize that autologous bone ma...
Detailed Description
Patients with type 1 or 2 Diabetes mellitus will be recruited according to eligibility criteria. Bone marrow mononuclear cells (BMMCs) will be separated from the bone marrow aspirate of each patient a...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetes
- Between 16 to 65 years of age
- Requiring daily exogenous insulin injection for the glycaemic control
- With poor β-cell function
- Body mass index (BMI) \< 28
Exclusion
- Acute or chronic infections
- Chronic uncompensated organic insufficiency including heart, liver, renal and lung
- Any malignancies, congenital or acquired immunodeficiency
- Hematological diseases or coagulopathy
- Acute or chronic pancreatitis
- History of thoracic or abdominal aorta diseases
- Allergy to iodine
- Pregnancy
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2014
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00465478
Start Date
March 1 2006
End Date
March 1 2014
Last Update
April 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012